Business Wire - August 11, 1999
Mr. Sanpietro commented: "These States have taken a giant leap forward in protecting the Health Care Workers as well as the patients." Approximately 800,000 to 1,000,000 needle sticks occur each year. Medi-Hut Co., Inc. will manufacture its own patented brand Anti-Stick Safety Syringes which has passed the FDA 510k approval process. The new safety syringe will incorporate a transparent sleeve into which the needle will automatically retract after use.
In a bipartisan move to nationalize the use of safer needles, Rep. Fortney "Pete" Stark (D-Ca) and Marge Roukema (R-NJ) joined together to introduce the Health Care Worker Needle Stick Prevention Act of 1999 in Congress in late May. Briefly stated, this act would require employees to use needleless IV systems and safety sharps, involve front-line workers in identifying and evaluating safety devices, and train workers on their use. Sen. Harry Reid (D-NV) is expected to introduce a similar bill in the Senate. Also, in conjunction, the Occupational Safety and Health administration will act swiftly to improve needle safety regulations says Labor Secretary Alexis Herman, looking for final action by this fall. "With everyone working for the same end, a safer working environment, Medi-Hut's product will fill the need of a safe, easy to use and competitively priced Anti-Stick Safety Syringe," stated Mr. Sanpietro.
Medi-Hut Co., Inc. was founded in 1982 and began trading publicly in February 1998. The Company private labels and recently announced their own "Elite brand" insulin syringes, condoms, alcohol preps, hot and cold packs, etc., and will manufacture its own patented brand anti-stick safety syringes which has also passed the FDA 510K approval process. The new safety syringe will incorporate a transparent sleeve into which the needle will automatically retract after use.
--30--MG/dx*
CONTACT: Medi-Hut Co., Inc. Joseph Sanpietro, President, 732/901-0606 or Brokers and Analysts Contact: Columbia Financial Group, Inc., 888/301-6271
990811
BW990801
Copyright © 1999 - Business Wire. All rights reserved. Reproduced with permission. Reproduction of this article (other than one copy for personal reference) must be cleared through the Business Wire, Permissions Desk, Business Wire, 1185 Avenue of the Americas, 3rd Floor, New York, NY 10036; Tel: (212) 575-8822; FAX: (212) 575-1854. http://www.businesswire.com.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Broadway Cares/Equity Fights AIDS, Elton John AIDS Foundation, the National Library of Medicine, Pacific Life Foundation and donations from users like you.
Always watch for outdated information. This article first appeared in 1999. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1999. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .